论文部分内容阅读
目的探讨辛伐他汀治疗青年无症状高脂血症的临床效果及对患者C反应蛋白(CRP)水平的影响。方法选取2014年9月—2015年9月永煤集团总医院收治的青年无症状高脂血症患者80例,随机分为研究组与对照组,各40例。研究组患者给予辛伐他汀治疗,对照组给予阿托伐他汀治疗,比较两组患者治疗前、治疗8周后血脂指标〔高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)〕、CRP水平、治疗效果及药物不良反应情况。结果治疗前两组患者HDL-C、TG、TC、LDL-C水平比较,差异无统计学意义(P>0.05);治疗后研究组患者HDL-C水平高于对照组,TG、TC、LDL-C水平低于对照组,差异有统计学意义(P<0.05)。治疗前两组患者CRP水平比较,差异无统计学意义(P>0.05);治疗后研究组患者CRP水平低于对照组,差异有统计学意义(P<0.05);治疗后研究组CRP水平低于治疗前,差异有统计学意义(P<0.05)。研究组治疗总有效率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论辛伐他汀治疗青年无症状高脂血症的临床效果确切,可有效降低CRP水平,改善血脂水平,且安全性高。
Objective To investigate the clinical effect of simvastatin on asymptomatic hyperlipidemia in young patients and its effect on the level of C-reactive protein (CRP). Methods Eighty young patients with asymptomatic hyperlipidemia admitted to Yongmei Group General Hospital from September 2014 to September 2015 were randomly divided into study group and control group, 40 cases in each group. Patients in the study group were given simvastatin, while those in the control group were given atorvastatin. The levels of serum lipids (HDL-C, triglyceride, triglyceride, Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C)], CRP level, therapeutic effect and adverse drug reactions. Results There was no significant difference in HDL-C, TG, TC and LDL-C levels between the two groups before treatment (P> 0.05). HDL-C levels in study group were higher than those in control group, TG, TC and LDL -C level was lower than the control group, the difference was statistically significant (P <0.05). There was no significant difference in CRP level between the two groups before treatment (P> 0.05). After treatment, the level of CRP in study group was lower than that in control group (P <0.05). After treatment, CRP level in study group was low Before treatment, the difference was statistically significant (P <0.05). The total effective rate of the study group was higher than that of the control group, the incidence of adverse reactions was lower than that of the control group, the difference was statistically significant (P <0.05). Conclusion Simvastatin is effective in treating asymptomatic hyperlipidemia in young people, which can effectively reduce the level of CRP, improve the blood lipid level and have high safety.